China Healthwise Holdings Full Year 2024 Earnings: HK$0.052 loss per share (vs HK$0.17 loss in FY 2023)

Simply Wall St

China Healthwise Holdings (HKG:348) Full Year 2024 Results

Key Financial Results

  • Revenue: HK$113.6m (down 22% from FY 2023).
  • Net loss: HK$40.3m (loss narrowed by 70% from FY 2023).
  • HK$0.052 loss per share (improved from HK$0.17 loss in FY 2023).
Our free stock report includes 4 warning signs investors should be aware of before investing in China Healthwise Holdings. Read for free now.
SEHK:348 Revenue and Expenses Breakdown May 5th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Chinese Health Products segment contributing a total revenue of HK$112.8m (99% of total revenue). Notably, cost of sales worth HK$78.6m amounted to 69% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to HK$29.0m (39% of total expenses). Explore how 348's revenue and expenses shape its earnings.

China Healthwise Holdings shares are down 6.3% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with China Healthwise Holdings (at least 3 which are a bit unpleasant), and understanding them should be part of your investment process.

Valuation is complex, but we're here to simplify it.

Discover if China Healthwise Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.